Skip to main content
Cellular Oncology logoLink to Cellular Oncology
. 2026 Jul 15;49(5):136. doi: 10.1007/s13402-026-01261-y

RNA-binding protein RALYL-mediated BCL11B RNA stability promotes immune escape in small cell lung cancer through transcriptional activation of BUB3

Jiayue Shao 1, Shuangqing Liu 1, Ling Qin 2, Ningning Fan 3, Qi Sun 1, Qingwei Meng 1,✉
PMCID: PMC13650239  PMID: 42455237

Abstract

Purpose

Small cell lung cancer (SCLC) is marked by rapid tumor growth and poor outcomes and necessitates effective treatments. This paper explores the molecular mechanisms by which BCL11B affects immune escape in SCLC.

Methods

Clinical tissues were collected to analyze BCL11B expression in SCLC, and the correlations between BCL11B and prognosis were examined. A co-culture system of SCLC and T cells was constructed to analyze immune escape. A transplanted tumor model was constructed, and the efficacy of PD-L1 immunotherapy was analyzed after BCL11B knockdown. The downstream targets of BCL11B were screened by bioinformatics, and BUB3 expression was verified in clinical tissues. The regulation of BCL11B on BUB3 was examined. Rescue assays were designed to analyze immune escape and tumor immunotherapy after BUB3 overexpression. RNA-binding proteins that regulated BCL11B were predicted, and their expression and prognostic significance in SCLC were analyzed. The effect of RALYL on immune escape was validated in vitro.

Results

BCL11B was notably increased in SCLC tissues and was associated with poor prognoses. BCL11B knockdown repressed SCLC cells from CD8+ T-mediated cytotoxicity, enhanced the efficacy of PD-L1 immunotherapy, and blocked SCLC progression. BCL11B transcriptionally activated BUB3 and enhanced PD-L1 expression. BUB3 overexpression reversed the impact of BCL11B knockdown on immune escape and the efficacy of immunotherapy. RALYL increased BCL11B mRNA stability to activate BUB3 and enhance PD-L1 expression. RALYL knockdown prevented immune escape in SCLC cells.

Conclusion

RALYL increases BCL11B stability and activates BUB3 to induce immune escape in SCLC by enhancing PD-L1 expression.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s13402-026-01261-y.

Keywords: BCL11B, Epigenetics, CD8+ T cells, Immunotherapy, Small cell lung cancer

Introduction

Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and is marked by high proliferative rates, rapid tumor growth, widespread metastases, and poor outcomes [1]. Surgical resection is not recommended for SCLC treatment, especially for those at advanced stages, primarily due to disappointing surgical outcomes [2]. Despite the high sensitivity of SCLC to ionizing radiation and chemotherapy, most patients may relapse and experience adverse events, leading to an average survival time of only about 10 months [3]. Immunotherapy-based treatment regimens are already available for SCLC, and two programmed cell death ligand 1 (PD-L1) inhibitors have been approved for first-line treatment [4]. Although some tumor cells can be discerned by the immune system, the inherent mechanisms of tumor cells stimulate tumor evasion and faster metastasis [5]. Therefore, preventing immune escape may be a fundamental way to block SCLC progression and metastasis.

B cell leukemia 11b (BCL11B), also known as CTIP2, is a zinc finger transcription factor that regulates diverse physiological and pathological processes, with particularly well-established functions in the immune system [6]. It has been demonstrated to function as both a genetic suppressor and activator, operating directly by binding to promoter regions, in addition to an indirect attachment to promoter-bound transcription factors [7]. BCL11B is indispensable for T-cell lineage commitment and maintenance in both mice and humans, and its loss leads to downregulation of T-cell-associated genes and acquisition of natural-killer-like features [8]. Furthermore, BCL11B has been shown to regulate gene expression programs through interactions with chromatin-remodeling complexes and transcriptional co-factors, thereby supporting T-cell survival and function [9]. Despite the clear delineation of immune cell functions, the tumor-intrinsic function of BCL11B, particularly in the context of SCLC, remains largely unexplored.

Budding uninhibited by benomyl 3 (BUB3) mainly functions in the activation of the spindle assembly checkpoint and telomere replication, and BUB3 upregulation is found in various human cancers [10]. Abnormal BUB3 expression is closely associated with mitotic defects, defective spindle gate function, chromosomal instability, aneuploidy, tumor cell proliferation, apoptosis, metastasis, and prognosis [11]. BUB3 has been discovered as an important hub gene in non-SCLC cell proliferation with oncogenic potential [12]. To date, the role of BUB3 in SCLC has not been established.

RNA-binding proteins are critical regulators of transcriptome dynamics, controlling multiple aspects of RNA metabolism, including RNA splicing, mRNA stability, mRNA localization, and translation [13, 14]. RALY RNA-binding protein-like (RALYL) is overexpressed in the Immunity_L subtype of SCLC and may be a potential mRNA vaccine antigen of SCLC [15]. However, the role of RALYL in immune escape during SCLC has not yet been reported. Based on the above information, this article intends to explore the underlying effects of BCL11B, BUB3, and RALYL on immune escape in SCLC.

Methods and materials

Clinical sample collection

From April 2014 to May 2020, tumor tissues with corresponding adjacent non-cancerous samples from 97 SCLC patients were collected at Harbin Medical University Cancer Hospital (approval no. KY2014-15). All patients were diagnosed with SCLC by a specialized oncologist based on clinicopathological findings. All patients underwent tumor resection and did not receive any chemotherapy or radiotherapy treatment before surgery. All patients signed an informed consent form. The clinical study was approved and reviewed by the ethical approval committee of Harbin Medical University Cancer Hospital and adhered to the tenets of the Declaration of Helsinki.

Isolation of single-cell suspensions from clinical tissue

Using the tumor dissociation kit, human (130-095-929, Miltenyi Biotec, Bergisch-Gladbach, Germany), SCLC tissues and adjacent non-cancerous tissues were dissociated into a single-cell suspension. In short, tumor tissues were minced into 2–4 mm pieces and added to a MACS tube containing an enzyme mixture for dissociation. The resulting cell suspension was transferred to a MACS SmartStrainer for filtration. Centrifugation at 300 g yielded a cell pellet, which was resuspended to obtain a single-cell suspension. Subsequently, tumor cells were isolated using the tumor cell isolation kit, human (130-108-339, Miltenyi Biotec). For para-cancerous tissues, cells were dissociated into a single-cell suspension and positively selected for epithelial cells using CD326 (EpCAM) microbeads, human (130-061-101, Miltenyi Biotec) as a control.

Cell culture

Human SCLC cells NCI-H446 (CL-0401, from a 61-year-old male patient with SCLC) and NCI-H526 (CL-0873, from a 55-year-old male patient with SCLC) were procured from Procell (Wuhan, Hubei, China) and cultured in RPMI-1640 medium with 10% FBS and 1% penicillin-streptomycin liquid at 37℃ and 5% CO2. Both have undergone STR identification and have been regularly tested to ensure freedom from mycoplasma infection. Primary CD8+ cytotoxic T cells were purchased from ATCC (PCS-800-017, Manassas, VA, USA, extracted by the manufacturer and of unknown sex) and cultured in RPMI-1640 medium plus 10% human serum albumin at 37℃ and 5% CO2. Primary CD8+ cytotoxic T cells were randomly tested to ensure freedom from mycoplasma infection. For inhibition of STAT3, SCLC cells were treated with 5 µM Stattic (HY-13818, MCE, Monmouth Junction, NJ, USA) for 48 h [16]; the control group was treated with an equal dose of DMSO.

Cell infection

To generate stably infected cell lines, lentiviral vectors knocking down BCL11B, overexpressing BCL11B, knocking down RALYL, and overexpressing BUB3 with their respective controls were obtained from VectorBuilder (Guangzhou, Guangdong, China). To perform BCL11B knockout, we obtained BCL11B CRISPR lentiviral vectors. The cells were infected with the lentiviral vector in the presence of polybrene for 48 h. Puromycin or neomycin was used to screen stably transduced SCLC cells after the medium was renewed. Transduction efficiency was assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or Western blot (WB).

Co-culture of T cells with SCLC cells

CD8+ T cells were incubated with CD3/CD28 magnetic beads to activate them via TCR/CD3 signaling and CD28 costimulation. The activated CD8+ T cells (2.5 × 10⁴) were then co-cultured with human SCLC cells (5 × 10⁴) in a microplate to establish a co-culture system (E: T = 2:1) [17], and the co-culture system was incubated for 24 h at 37℃ in a 5% CO2 incubator. The co-culture supernatant was collected, and all cells were collected. Besides, 10 µg/mL Durvalumab (HY-P9919A, MCE) was supplemented to the co-culture system, and control cells were treated with an equal dose of human IgG1 kappa, isotype control (HY-P99001, MCE) [18].

SCLC cell survival analysis

Before conducting co-culture experiments with CD8+ T cells and SCLC cells, we infected SCLC cells with Firefly Luciferase Lentivirus (#78740, BPS Bioscience, San Diego, CA, USA). In short, Firefly Luciferase Lentivirus was added to initiate infection. The infected cells were incubated in a 37 °C, 5% CO₂ incubator for 24 h, after which the medium was replaced with fresh complete medium and cultured for an additional 24 h. To obtain SCLC cell lines stably expressing firefly luciferase, the infected cells were subjected to antibiotic selection using Geneticin/G418. After co-culturing the cells with CD8+ T cells, the luciferase substrate solution was added and incubated for 5 min at room temperature in the dark, and the luciferase signal was measured using a microplate reader. Since the luciferase signal originates solely from tumor cells, the relative luciferase activity can be used to reflect changes in the survival of viable tumor cells following co-culture. The relative luciferase activity for each group was calculated as a percentage (%) of the luciferase activity in the control group.

Cytotoxicity assay

After the co-culture, cytotoxicity was assessed by analyzing the lactate dehydrogenase (LDH) content in the supernatant of the co-culture system according to the LDH cytotoxicity assay kit (C0016, Beyotime, Shanghai, China). The LDH assay working solution (60 µL) was added to the collected supernatant, mixed well, and incubated at room temperature (RT) in the dark for 30 min. Subsequently, the absorbance was read at 490 nm. Cytotoxicity (%) was calculated: (absorbance of tested samples - absorbance of control wells)/(absorbance of maximum enzyme activity of the cells - absorbance of control wells) × 100.

Animal experiments

To mimic the anti-tumor response of CD8+ T cells in the tumor microenvironment during SCLC development, we purchased female humanized (huPBMC-NOG-dKO) mice from Vital River Laboratory Animal Technology (Beijing, China). This model was established using a NOG-dKO immunodeficient background and reconstructed the human immune system using human peripheral blood mononuclear cells (huPBMCs). At the time of purchase, the supplier had already completed the transplantation of huPBMCs and the corresponding quality control tests to confirm the reconstitution of human immune cells in the mice. Mice were housed in SPF-grade animal facilities under a 12-h light/dark cycle with free access to food and water. Temperature was maintained at 22 °C, and humidity was kept between 40% and 60%. The animal study was approved by the Ethics Review Committee of Harbin Medical University Cancer Hospital (approval no. KY2021-15) and complied with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.

Untreated NCI-H446 cells, NCI-H446 cells with BCL11B knockdown or knockout, RALYL knockdown, or BCL11B knockdown + BUB3 overexpression were collected. Then, 100 µL of single-cell suspension containing 5 × 106 NCI-H446 cells was subcutaneously administered into the right side of 8-week-old mice (approximately 18 g, n = 5) [19, 20]. PD-L1 inhibition in mice was performed by weekly intraperitoneal injection of 10 mg/kg of Durvalumab when the tumor had grown to about 100 mm³ (defined as day 0). Tumor volume was measured every 3 days using vernier calipers, and tumor size was calculated as V = (S2 × L)/2, where L is the longest diameter of the tumor, and S is the shortest diameter of the tumor. After 21 days, mice were euthanized by intraperitoneal injection of 150 mg/kg sodium pentobarbital, and tumor tissues were collected and weighed. A portion of the tumor tissues was formalin-fixed overnight and paraffin-embedded, and the remaining tumor tissues were used to prepare single-cell suspensions.

Immunohistochemistry (IHC)

Paraffin-embedded sections of clinical samples were deparaffinized with xylene and rehydrated with ethanol. After antigen retrieval by microwave heating, the sections were incubated with 3% hydrogen peroxide to remove endogenous peroxidase and sealed with 10% goat serum to prevent non-specific binding. The sections were incubated with antibodies against BCL11B (1:200, 55414-1-AP, Proteintech, Wuhan, Hubei, China), BUB3 (1:100, PA5-29781, Thermo Fisher), and RALYL (1:1000, PA5-63193, Thermo Fisher) overnight at 4℃. The excess primary antibody was removed after incubation. Afterward, the sections were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:50, AS014, Abclonal, Wuhan, Hubei, China) secondary antibody at RT for 2 h. Color development was performed using DAB, and the nuclei were counterstained with hematoxylin. IHC positivity was scored using the H-score: 0 × (percentage of unstained tumor cells) + 1 × (percentage of weakly expressed) + 2 × (percentage of moderately expressed) + 3 × (percentage of strongly expressed) [21].

Immunofluorescence

Paraffin-embedded sections of clinical samples were dewaxed with xylene, rehydrated with ethanol, and blocked with 10% goat serum. They were incubated overnight at 4 °C with the following antibodies: rabbit anti-CD68 (1:1000, ab303565, Abcam, Cambridge, MA, USA), rabbit anti-CD4 (1:500, A26036PM, Abclonal), rabbit anti-CD8 (1:50, A23305PM, Abclonal), rabbit anti-myeloperoxidase (MPO, 1:1000, ab208670, Abcam), rabbit anti-CD83 (1:100, ab275032, Abcam), rabbit anti-BCL11B (1:200, 55414-1-AP, Proteintech), mouse anti-TTF-1 (1:100, MA5-13961, Thermo Fisher), and mouse anti-CD3 (1:200, 60181-1-Ig, Proteintech) at 4 °C overnight. The samples were washed again and incubated with the corresponding secondary antibodies: goat anti-rabbit IgG (H + L), highly cross-adsorbed secondary antibody, Alexa Fluor 647 (1:200, A-21245, Thermo Fisher), goat anti-mouse IgG (H + L) Superclonal secondary antibody, Alexa Fluor 488 (1:200, A-11029, Thermo Fisher), and goat anti-mouse IgG (DyLight488) (1:100, GTX213111-04, GeneTex, Inc., Alton Pkwy Irvine, CA, USA) at RT for 2 h. After DAPI staining of cell nuclei, coverslips were sealed with a coverslip mounting medium containing anti-fluorescence quenching agents and viewed under a fluorescence microscope.

TdT-mediated dUTP nick-end labeling (TUNEL)

One-step TUNEL in situ apoptosis kit (Green, Elab Fluor 488) (E-CK-A321, Elabscience, Houston, TX, USA) was used to examine apoptosis in vitro and in vivo. After the co-culture, cells were fixed in 4% paraformaldehyde for 20 min and permeabilized with 0.2% Triton X-100 for 10 min. Paraffin-embedded sections of mouse tumor tissues were deparaffinized and rehydrated, and the samples were immersed in PBS. The sections were treated with proteinase K working solution for 20 min at 37℃. The samples were equilibrated in a wet box at 37 °C for 30 min with TdT equilibration buffer. After the TdT equilibration buffer was removed, the labeling working solution was added and incubated in a wet box at 37 °C for 1 h in the dark. DAPI staining was used for cell nuclei. The slices were sealed using a sealing solution containing an anti-fluorescence quencher. The percentage of TUNEL-positive cells was calculated.

Flow cytometry

The co-cultured T cells were enriched using magnetic beads, and cell permeabilization was conducted using eBioscience flow intracellular fixation and permeabilization buffer (88-8824-00, Thermo Fisher). The cells were incubated with antibodies against APC-Granzyme B (GZMB) (GRB05, Thermo Fisher) and PE-Perforin (12-9994-42, Thermo Fisher) for 30 min at RT. Cells were detected on a flow cytometer and analyzed using CytExpert software (Beckman Coulter, Inc., Chaska, MN, USA).

For the infiltration assay of CD8+ T cells, mouse tumor tissues were minced and incubated with RPMI-1640 medium containing 80 U/mL DNase, 300 U/mL type I collagenase, and HEPES for 45 min at 37℃. The tissues were filtered through a 70 μm filter, and red blood cells were separated into single-cell suspensions using red blood cell lysis solution (130-094-183, Miltenyi Biotec). Afterward, tumors were resuspended into single-cell suspensions. Non-specific binding was blocked using human TruStain FcX (Fc Receptor Blocking Solution) (422301, BioLegend, San Diego, CA, USA). FITC-CD3 (11-0037-42, Thermo Fisher) and PE-CD8 (12-0088-42, Thermo Fisher) were added for incubation at RT for 30 min.

Enzyme-linked immunosorbent assay (ELISA)

The levels of GZMB and Perforin in mouse tumor tissues were assayed using the human GZMB ELISA kit (ELH-GZMB, Raybiotech, Norcross, GA, USA) and human Perforin ELISA kit (A2333, Antibodies, Davis, CA, USA).

Chromatin immunoprecipitation (ChIP)

Human SCLC cells were detached with trypsin, washed twice with PBS, and cross-linked in a final concentration of 1% formaldehyde solution for 10 min. Crosslinking was terminated by a 5-min treatment with 1.25 M glycine at RT. Cells were lysed and sonicated to yield chromatin fragments of 200 bp. Fragmented chromatin was immunoprecipitated using BCL11B (1:50, 55414-1-AP, Proteintech), RALYL (1:50, 17179-1-AP, Proteintech), and rabbit IgG control (30000-0-AP, Proteintech) and incubated overnight at 4℃. Protein A/G magnetic bead-coupled immune complexes were added. After magnetic beads were washed in RIPA buffer (50 mM HEPES, pH = 7.5, 500 mM LiCl, 1 mM EDTA, 1.0% NP-40, 0.7% Na-Deoxycholate), the beads were eluted using an elution buffer (50 mM Tris-HCl, pH = 8.0, 10 mM EDTA, 1.0% SDS). DNA fragments were extracted by de-crosslinking in NaCl with proteinase K. They were analyzed by agarose gel electrophoresis with promoter primers specific to BUB3: left primer: TGGTAAAATGAGCCCACGTG; right primer: CTCCAGTGTAGACCTGCCAT, and BCL11B: left primer: CCGGGCTGCAAAGAAACTTT; right primer: GGAGCTCATCACCCGTAAGT.

RNA immunoprecipitation (RIP)

To verify the interaction between RALYL and BCL11B mRNA, an RIP assay was performed. Cells were lysed using pre-chilled RIPA lysis buffer, with protease inhibitors and RNase inhibitors added to the lysis buffer to minimize protein and RNA degradation. After incubation on ice, the lysate was centrifuged at high speed at 4 °C, and the supernatant was collected. A portion of the lysate was retained as an input control, and the remaining lysate was incubated with magnetic beads coupled to RALYL (1:50, 17179-1-AP, Proteintech) and rabbit IgG (30000-0-AP, Proteintech) for 6 h at 4℃. The magnetic beads were washed with the RIP wash buffer to remove nonspecific adsorption. Protein-RNA complexes with magnetic beads were detached with proteinase K at 55℃ to purify RNA and elute RNA from the beads. After RNA extraction, the extracted RNA was reverse-transcribed, and the enrichment levels of BCL11B mRNA in the RALYL immunoprecipitation group were analyzed by RT-qPCR or agarose gel electrophoresis.

Dual-luciferase assay

The BUB3 and BCL11B promoters were amplified and cloned into pGL3-basic vectors by restriction enzymes to construct the reporter plasmid, which was transfected into human SCLC cells with BCL11B or RALYL knockdown using Lipofectamine 2000. After 48 h, dual-luciferase activity was assessed using a dual-luciferase assay system.

Regarding the study of the binding region between RALYL and BCL11B, we cloned the BCL11B 3’UTR into the psiCHECK-2 vector using restriction enzymes. We transfected the reporter plasmid into RALYL-knockdown SCLC cells using Lipofectamine 2000. Forty-eight hours after transfection, dual-luciferase activity was assessed using a dual-luciferase reporter assay system.

RNA half-life assay

Human SCLC cells with RALYL knockdown were seeded in 6-well plates and treated with 5 µg/mL actinomycin D (A9415, Sigma-Aldrich, St. Louis, MO, USA) to inhibit de novo RNA transcription. The cells were collected at 0 h, 1 h, 2 h, and 4 h of treatment. Total RNA was extracted using TRIzol reagent, and the RNA concentration and purity were determined. Subsequently, equal amounts of RNA were isolated to synthesize cDNA for reverse transcription. RT-qPCR was used to detect the relative expression of BCL11B mRNA at each time point. The expression at 0 h was used as the normalization reference to calculate the relative proportion of remaining mRNA at each time point, thereby assessing the stability of BCL11B mRNA and changes in its half-life.

RNA-pull down

RNA probes were constructed using the 5’UTR, 3’UTR, and coding sequence (CDS) of BCL11B mRNA, and biotin-labeled RNA probes were synthesized. SCLC cells were lysed with lysis buffer, centrifuged to collect the supernatant, and incubated with the probe at 4 °C for 4 h. Streptavidin magnetic beads were added to enrich the RNA-protein complex. After incubation, the magnetic beads were washed, and the protein from the beads was eluted using the protein loading buffer. Finally, the enriched RALYL protein was detected via WB.

RT-qPCR

Total RNA was extracted from clinical tissues and human SCLC cells using the RNeasy Plus Mini Kit for RNA Isolation (74134, Qiagen, Hilden, Germany). cDNA was synthesized from RNA by RT-qPCR using the QuantiTect Reverse Transcription kit (205311, Qiagen), and real-time PCR was performed using QuantiTect PCR kits (204343, Qiagen). qPCR reactions were run on a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA). Gene expression was quantitatively analyzed using the 2−ΔΔCT method, with GAPDH as an internal reference. The primers used are shown in Table S1.

WB

Human SCLC cells and mouse tumor tissue were lysed in RIPA buffer, and cell lysates were centrifuged at 4000 g for 20 min at 4℃. The supernatant was transferred to a new tube. Total protein extracts were quantified using the BCA method, and 50 µg of protein was separated on 10–15% SDS-PAGE and transferred to PVDF membranes. Membranes were sealed with 5% skimmed milk powder for 1 h at RT and incubated at 4℃ with primary antibodies against BCL11B (1:1000, 55414-1-AP, Proteintech), BUB3 (1:1000, PA5-29781, Thermo Fisher), PD-L1 (1:1000, ab237726, Abcam), SRC (1:10000, ab109381, Abcam), STAT3 (1:500, A1192, Abclonal), RALYL (1:500, 17179-1-AP, Proteintech), and GAPDH (1:1000, #2118, CST, Beverly, MA, USA) overnight. After the excess primary antibodies were washed away, the membranes were probed with HRP-conjugated goat-anti-rabbit IgG (1:2000, AS014, Abclonal) at RT for 1 h. After proteins were developed using ECL chemiluminescence, the gray value of protein blots was measured using ImageJ, and the expression of target proteins was calculated as the ratio of the gray value to that of the internal reference protein.

Statistical analysis

GraphPad Prism 10 (GraphPad Software Inc., San Diego, CA, USA) was used for data analysis. Data are presented as mean ± SEM of at least three independent experiments. Pearson’s coefficient was adopted to check the correlation between the two variables. Fisher’s exact test was used to analyze the relationship among clinical parameters in patients with SCLC. The relationship between gene expression and patient prognosis was analyzed using the Log-rank (Mantel-Cox) test. Pairwise comparisons were made by Student’s t-test, and multigroup comparisons were analyzed by one-way or two-way ANOVA. Tukey’s multiple comparisons test and Šídák’s multiple comparisons test were used for post-hoc tests. p < 0.05 was considered statistically significant.

Results

BCL11B upregulation correlates with low CD8+ T cell infiltration and predicts poor patient prognosis in SCLC

The GSE149507 dataset was selected from the GEO database, and the transcriptomic differences between 18 pairs of SCLC tissues and adjacent lung tissues were analyzed using p. adj < 0.05 and |log2FoldChange (FC)| > 1 as the screening criteria (Fig. S1A). SCLC-related genes were downloaded from the GeneCards database (https://www.genecards.org/) using the keyword “small cell lung cancer”. Human transcription factors (TFs) were downloaded from AnimalTFDB v4.0 (https://guolab.wchscu.cn/AnimalTFDB4//#/). Genes in the top 50% of relevance score for immune escape were downloaded from the GeneCards database (https://www.genecards.org/) using the keyword “immune escape”. Differentially expressed genes (DEGs) in the GSE149507, SCLC-related genes, human TFs, and immune escape-related genes were cross-screened in Jvenn (https://jvenn.toulouse.inrae.fr/app/example.html) (Fig. S1B), and the obtained intersecting genes were analyzed for KEGG enrichment (Fig. S1C). Among the KEGG-enriched pathways, transcriptional misregulation in cancer was the pathway with the most significant p-value. Among the nine genes located in it, i.e. ZEB1 (Log FC = -1.093), MITF (Log FC = -1.087), MYC (Log FC = -1.288), FOXO1 (Log FC = -1.278), PPARG (Log FC = -2.388), CEBPA (Log FC = -1.215), ERG (Log FC =-1.643), ZBTB16 (Log FC =-2.33), and BCL11B (Log FC = 1.069), only BCL11B was highly expressed.

RT-qPCR and IHC assays showed increased BCL11B expression in tumor tissues of SCLC patients (Fig. 1A, B). We performed dual-labeling immunofluorescence staining for TTF-1 or CD3 and BCL11B, revealing significant overexpression of BCL11B in SCLC cells. Additionally, substantial expression of BCL11B was observed in T cells within the tumor tissue (Fig. 1C). To confirm that the increased expression of BCL11B in SCLC primarily correlates with the proliferation of tumor cells within the tumor microenvironment, we isolated tumor cells from SCLC specimens. RT-qPCR results demonstrated that BCL11B expression was elevated in tumor cells compared to normal epithelial cells adjacent to the tumor (Fig. 1D). Patients were categorized into high expression (n = 46) and low expression (n = 51) groups based on the mean mRNA expression of BCL11B. Patients with high BCL11B expression had worse prognoses (Fig. 1E). Immunofluorescence showed that high BCL11B expression was associated with lower CD8+ T-cell infiltration (Fig. 1F). BCL11B expression was inversely correlated with CD8+ T-cell infiltration in tumor tissues (Fig. 1G). In addition, BCL11B expression was not associated with patients’ sex, age, or smoking history, while there were significant correlations with T stage, N stage, and TNM stage (Table S2). The multivariate Cox proportional hazards regression analysis included BCL11B mRNA expression, stage, age, and sex. Unexpectedly, age was significantly associated with patient prognosis (HR = 1.032, 95% CI: 1.005–1.061, p = 0.020). In contrast, BCL11B mRNA expression was not statistically significant in relation to patient prognosis (HR = 1.520, 95% CI: 0.908–2.544, p = 0.111). At the same time, neither the TNM stage (HR = 0.830, 95% CI: 0.486–1.418, p = 0.495) nor gender (HR = 1.248, 95% CI: 0.784–1.987, p = 0.349) was associated with prognosis (Table S3). The above results indicated that, after adjusting for age, TNM stage, and gender, BCL11B mRNA expression did not demonstrate independent prognostic significance.

Fig. 1.

Fig. 1

BCL11B is a new immunotherapeutic candidate in SCLC. A, RT-qPCR of BCL11B expression in tumor and adjacent tissues of SCLC patients (n = 97); B, IHC assay of BCL11B protein expression in tumor and adjacent tissues of SCLC patients (n = 97); C, Dual-labeling immunofluorescence analysis of BCL11B expression in tumor cells and T cells within SCLC tumor tissue; D, RT-qPCR of BCL11B expression in epithelial cells isolated from clinical tumor margins and tumor cells isolated from SCLC tumor tissues (n = 97); E, Log-rank (Mantel-Cox) test to analyze the correlation between BCL11B mean expression and 5-year survival of SCLC patients (n = 97); F, Immunofluorescence to detect the infiltration of macrophages, CD4+ T cells, CD8+ T cells, neutrophils, and dendritic cells in tumor tissues of SCLC with high versus low BCL11B mean expression; G, Pearson’s correlation analysis between BCL11B expression and CD8+ T cell infiltration in SCLC tissues. Paired t-test was applied for comparisons between two groups, the Log-rank (Mantel-Cox) test was used for survival analysis, and Pearson’s correlation was used for correlation analysis

To determine whether increased BCL11B expression in tumor cells is associated with prognosis and CD8+ infiltration, we further stratified patients into high-expression and low-expression groups based on the mean BCL11B expression in isolated single tumor cells. We analyzed the association between BCL11B expression in tumor cells and CD8+ T-cell infiltration in SCLC, as well as patient prognosis. BCL11B expression in tumor cells was associated with poor patient prognosis (Fig. S1D), and its high expression was associated with reduced CD8+ T-cell infiltration (Fig. S1E). Furthermore, its expression was negatively correlated with CD8+ T-cell infiltration (Fig. S1F).

Knockdown of BCL11B in SCLC cells enhances the antitumor activity of CD8 + T cells

BCL11B was knocked down in NCI-H446 and NCI-H526 cells (Fig. 2A, B). The co-culture system of SCLC cells and CD8+ T cells was further constructed (Fig. 2C). After co-culture, BCL11B knockdown increased cytotoxicity in the co-culture system (Fig. 2D). Analyzing luciferase activity expressed by tumor cells after co-culture revealed that BCL11B knockdown in SCLC cells enhanced tumor killing of CD8+ T cells (Fig. 2E). TUNEL showed (Fig. 2F) that BCL11B knockdown in SCLC cells strengthened CD8+ T cell-induced apoptosis of SCLC cells in the co-culture system. Flow cytometry showed that the ratio of GZMB+ and Perforin+ positive cells in CD8+ T cells was greatly increased after BCL11B knockdown in SCLC cells (Fig. 2G, H). We knocked out BCL11B in NCI-H446 and NCI-H526 cells using CRISPR-Cas9 technology. WB analysis confirmed its protein depletion (Fig. S2A). The deletion of BCL11B in SCLC cells further induced the death of SCLC cells in the CD8+ T cell-tumor cell co-culture microenvironment. This led to increased cytotoxicity (Fig. S2B), reduced survival of cells after co-culture (Fig. S2C), a marked increase in apoptosis of SCLC cells (Fig. S2D), and increased GZMB+ and Perforin+ cell rates (Fig. S2E, F).

Fig. 2.

Fig. 2

BCL11B knockdown inhibits SCLC cell escape from CD8+ T cell-mediated immune surveillance. A-B, RT-qPCR and WB detection of BCL11B expression in SCLC cells after BCL11B knockdown; C, Flowchart of co-culture of CD8+ T cells and SCLC cells; D, Cytotoxicity detection kit to analyze the cytotoxicity in the co-culture system; E, Luciferase activity assay to analyze the survival of SCLC cells after co-culture; F, TUNEL to detect cell apoptosis in the co-culture system; G-H, Flow cytometry to detect the population of GZMB- and Perforin-positive cells in CD8+ T cells after co-culture. Two-way ANOVA was applied for comparisons among multiple groups, and the experiment was repeated three times independently

BCL11B knockdown improves the efficacy of anti-PD-L1

Next, we inoculated NCI-H446 cells with BCL11BKD into humanized mice and treated them with anti-PD-L1 antibody (Durvalumab) (Fig. 3A). BCL11BKD alone suppressed tumor growth. BCL11B knockdown enhanced the efficacy of Durvalumab, resulting in suppression of tumor growth (Fig. 3B, Fig. S3A). WB results showed reduced BCL11B expression in tumor tissues formed by NCI-H446 cells with BCL11BKD (Fig. S3B). TUNEL confirmed that BCL11B knockdown in tumor tissues increased apoptosis and enhanced the efficacy of the anti-PD-L1 antibody, thereby further intensifying apoptosis (Fig. 3C). Flow cytometry revealed that the percentage of CD8+ T cells in single-cell suspensions of tumor tissues was notably increased after BCL11B knockdown. Knockdown of BCL11B enhanced the induction of anti-PD-L1 antibody on T cell activation (Fig. 3D). GZMB and Perforin levels in tumor tissues were also increased after BCL11B knockdown (Fig. 3E).

Fig. 3.

Fig. 3

BCL11B knockdown improves the efficacy of anti-PD-L1 antibody in vivo. A, Flowchart of the xenograft tumor model and treatment with anti-PD-L1 antibody; B, Analysis of tumor growth and weight in mice; C, TUNEL to detect apoptosis in the tumor tissues; D, Flow cytometry to detect the percentage of CD3+CD8+ T cells in single-cell suspensions of tumor tissues from mice; E, ELISA to detect GZMB and Perforin levels in the tumor tissues. One-way ANOVA was applied for comparisons among multiple groups, with 5 mice in each group

We also analyzed the impact of BCL11B knockout on tumor growth in these mice. BCL11B knockout in tumor cells markedly impeded tumor growth (Fig. S4A), reduced tumor weight (Fig. S4B), and increased apoptosis in tumor tissues (Fig. S4C). Increased infiltration of CD3+CD8+ T cells in the tumor microenvironment (Fig. S4D) was accompanied by a significant rise in their secreted GZMB and perforin levels (Fig. S4E). This demonstrated that BCL11B intervention enhanced CD8+ T cell antitumor activity and inhibited the growth of SCLC tumors.

BCL11B regulates the transcriptional activation of BUB3 to trigger PD-L1 expression

The potential targets of BCL11B were predicted in ChIP-Atlas (https://chip-atlas.org/), and those with an average > 500 were taken for cross-screening with DEGs in the GSE149507 dataset, SCLC-related genes, and immune escape-related genes, and five intersecting genes were obtained (Fig. S5A). The protein interaction maps of the intersecting genes were plotted on the STRING website (Fig. S5B). Only BUB3 and MCM7 showed interactions, while the mechanism of MCM7 [22] has been elucidated in lung cancers. ChIP-seq analysis at UCSC (http://genome.ucsc.edu/cgi-bin/) showed a binding peak of BCL11B in the BUB3 promoter region (chr10: 123154063–123154411) (Fig. S5C). SangerBox tool (http://vip.sangerbox.com/home.html) showed that BCL11B was positively correlated with BUB3 expression (Fig. S5D). BUB3 (Log FC = 1.383) was highly expressed in the SCLC tissues in the GSE149507 dataset.

BUB3 was considerably increased in the SCLC tissues of our cohort (n = 97) (Fig. 4A, B). BUB3 was positively correlated with BCL11B expression in clinical SCLC tissues (Fig. 4C). Patients were divided into high-expression and low-expression groups based on the mean BUB3 mRNA expression levels in SCLC tissues, and their survival was analyzed. SCLC patients with high expression of BUB3 had shorter survival (Fig. 4D).

Fig. 4.

Fig. 4

BCL11B regulates transcriptional activation of BUB3 to induce PD-L1 expression. A, RT-qPCR to analyze BUB3 expression in clinical SCLC and adjacent samples (n = 97); B, IHC to analyze BUB3 expression in clinical SCLC samples and adjacent samples (n = 97); C, Pearson’s correlation analysis of BCL11B and BUB3 expression in SCLC tissues (n = 97); D, The survival of SCLC patients with high or low BUB3 mean expression; E, RT-qPCR analysis of BUB3 mRNA expression in SCLC cells after BCL11B knockdown; F, WB assay of BUB3 and PD-L1 protein expression in SCLC cells after BCL11B knockdown; G, Dual-luciferase assay to analyze the luciferase activity of the BUB3 promoter after BCL11B knockdown in SCLC cells; H, ChIP to analyze the binding of BCL11B to the BUB3 promoter in SCLC; Paired t-test was applied for comparisons between two groups. Two-way ANOVA was applied for comparisons among multiple groups. The experiment was repeated independently three times

BCL11B knockdown inhibited BUB3 and PD-L1 protein expression in SCLC cells (Fig. 4E, F). In BCL11B knockout cells, we observed significant BUB3 downregulation (Fig. S6A, B). Dual-luciferase assay evinced that BCL11B knockdown in SCLC cells resulted in a reduction of transcriptional activity in the BUB3 promoter (Fig. 4G). ChIP assay revealed binding of anti-BCL11B at the BUB3 promoter (Fig. 4H).

BUB3 overexpression reverses the inhibitory effect of BCL11B knockdown on immune escape in SCLC cells

BUB3 was overexpressed in SCLC cells with BCL11B knockdown (Fig. 5A). WB showed that BUB3 and PD-L1 protein levels were restored (Fig. 5B). Co-culture of SCLC cells with CD8+ T cells revealed that in the presence of BCL11B knockdown, BUB3 overexpression decreased cytotoxicity in the co-culture system (Fig. 5C), increased SCLC cell survival (Fig. 5D), and decreased SCLC cell apoptosis in the co-culture system (Fig. 5E). The reduced ratio of GZMB+ and Perforin+ cells was observed in CD8+ T cells after co-culture with SCLC cells overexpressing BUB3 (Fig. 5F). Durvalumab was added to the co-culture system for PD-L1 inhibition (Fig. 5G), which increased cytotoxicity and decreased surviving SCLC cells (Fig. 5H, I), indicating that BUB3 overexpression repressed the immune surveillance mediated by PD-L1. In cells in which BCL11B was knocked down, we observed a significant decrease in the protein expression of SRC and STAT3. However, upon overexpression of BUB3, the SRC/STAT3 signaling pathway was significantly activated (Fig. S6C). Furthermore, we used Static to inhibit STAT3 activity. We observed that, following treatment with Static, the increase in PD-L1 expression induced by BUB3 overexpression was significantly suppressed (Fig. S6D). This result indicates that the SRC/STAT3 pathway is involved in the molecular mechanism by which BUB3 regulates PD-L1 expression.

Fig. 5.

Fig. 5

BUB3 overexpression reverses the inhibitory effect of BCL11B knockdown on immune escape in SCLC cells. A, RT-qPCR detection of BUB3 expression in SCLC cells infected with BCL11BKD 2# + NCOE or BCL11BKD 2# + BUB3OE; B, WB detection of BUB3 and PD-L1 expression in SCLC cells infected with BCL11BKD 2# + NCOE or BCL11BKD 2# + BUB3OE; C, Cytotoxicity detection kit to detect cytotoxicity in the co-culture system; D, Luciferase activity assay to detect SCLC cell survival; E, TUNEL to detect cell apoptosis in the co-culture system; F, Flow cytometry to determine the percentage of GZMB+ and Perforin+ cells in T cells; G, Flow chart of PD-L1 inhibitor (Durvalumab) addition in the co-culture system; H, Cytotoxicity detection kit to detect cytotoxicity in the co-culture system with PD-L1 inhibitor; I, Luciferase activity assay to detect SCLC cell survival after co-culture with PD-L1 inhibitor. Two-way ANOVA was applied for comparisons among multiple groups. The experiments were repeated three times independently

BUB3 overexpression impairs the efficacy of anti-PD-L1 treatment in vivo

Next, in mice, we established a tumor model using SCLC cells with BCL11BKD + NCOE or BUB3OE. Following treatment with Durvalumab, BUB3OE accelerated tumor growth while simultaneously diminishing the therapeutic efficacy of Durvalumab (Fig. 6A, B). WB analysis revealed that BUB3OE increased BUB3 and PD-L1 levels in tumor tissues (Fig. 6C), reversing the effects of BCL11B knockdown. Overexpression of BUB3 also reduced apoptosis in tumor tissues in the presence or absence of Durvalumab (Fig. 6D). In addition, BUB3 overexpression inhibited the tumor-killing efficacy of CD8+ T cells in tumor tissues with or without Durvalumab treatment, which further promoted immune escape (Fig. 6E-G). This demonstrated that the suppression of tumor growth and the enhanced efficacy of anti-PD-L1 therapy resulting from BCL11B downregulation were associated with reduced BUB3 expression. Overexpression of BUB3 mitigated the effects of BCL11B knockdown.

Fig. 6.

Fig. 6

BUB3 overexpression impairs the efficacy of anti-PD-L1 antibody in vivo. A, Analysis of tumor volume in mouse formed by SCLC cells with BCL11B knockdown and BUB3 overexpression and treated with anti-PD-L1 antibody; B, Analysis of tumor weight in mouse formed by SCLC cells with BCL11B knockdown and BUB3 overexpression and treated with anti-PD-L1 antibody; C, WB detection of BUB3 and PD-L1 expression in tumor tissues of mice; D, TUNEL detection of apoptosis in tumor tissues; E, Flow cytometry of the population of CD8+ T-cells in single-cell suspensions in tumor tissues; F-G, ELISA to detect GZMB and Perforin levels in tumor tissues. One-way or two-way ANOVA was applied for comparisons among multiple groups, with five mice per group

BCL11B expression is regulated by the RNA-binding protein RALYL

The top 500 known RNA-binding proteins (based on prediction score) that may act with BCL11B were obtained from RNAct (https://rnact.tartaglialab.com/) and cross-screened against DEGs in the GSE149507 and SCLC-related genes (Fig. S7A). Six intersecting genes were obtained: CHGA [23], RALYL, HTATSF1 [24], HOOK1 [25], DEK [26], and LRRFIP1 [27]. RALYL (Log FC = 3.001) was elevated in the GSE149507 dataset. catRAPID (http://s.tartaglialab.com/page/catrapid_group) analysis revealed that the RALYL protein sequence (NP_776247.3) interacted with the BCL11B mRNA (NM_138576.4) (Fig. S7B). Sangerbox tool analysis showed a positive correlation between RALYL and BCL11B expression in SCLC samples from the GSE149507 dataset (Fig. S7C).

RALYL was notably increased in SCLC tissues of our cohort (n = 97) (Fig. 7A, B). RALYL expression was positively correlated with BCL11B and BUB3 expression (Fig. 7C). Similarly, patients were divided into high- and low-expression groups based on the mean RALYL expression in SCLC tissues. Analysis of the association between RALYL expression and patients’ prognosis revealed that high RALYL expression predicted poor prognoses for SCLC patients (Fig. 7D). In SCLC cells, RALYL was knocked down, and the shRNA with the optimal knockdown efficiency was selected (Fig. 7E, F). RALYL knockdown reduced BCL11B and BUB3 mRNA and protein levels (Fig. 7G). RIP confirmed a binding relationship between RALYL and BCL11B mRNA (Fig. 7H). RNA half-life assay revealed that RALYL knockdown impaired BCL11B mRNA stability (Fig. 7I). To confirm that RALYL affected BCL11B expression solely through post-transcriptional regulation (Fig. S6E), we analyzed the effect of RALYL knockdown on BCL11B promoter activity using a dual-luciferase assay. RALYL did not affect BCL11B promoter transcriptional activity. Additionally, ChIP experiments confirmed that RALYL did not bind to the BCL11B promoter fragment (Fig. S6F). In vitro, we introduced the BCL11B 3’UTR into a reporter plasmid constructed using psiCHECK-2 and transfected it into cells stably knocked down for RALYL. RALYL knockdown reduced luciferase activity (Fig. S6G), indicating that the interaction between RALYL and BCL11B is mediated by the BCL11B 3’UTR. Additionally, in our RNA pull-down experiments, we designed BCL11B 5’UTR, CDS, and 3’UTR probes to detect RALYL binding. Only the 3’UTR probe enriched RALYL protein (Fig. S6H), indicating that RALYL binds specifically to the 3’UTR of BCL11B.

Fig. 7.

Fig. 7

BCL11B expression is regulated by the RNA-binding protein RALYL. A-B, RT-qPCR and IHC to detect RALYL expression in clinical SCLC tissues and adjacent tissues (n = 97); C, Pearson’s correlation analysis to explore the correlation between RALYL and BCL11B or BUB3 expression in SCLC tissues (n = 97); D, The survival analysis of SCLC patients with high (n = 49) or low RALYL (n = 48) mean expression; E-F, RT-qPCR and WB detection of RALYL expression after knockdown of RALYL in SCLC cells; G, RT-qPCR and WB detection of BCL11B and BUB3 expression after knockdown of RALYL in SCLC cells; H, RIP-qPCR and agarose gel electrophoresis detection of the binding of RALYL to BCL11B mRNA in SCLC cells; I, Actinomycin D-mediated RNA half-life assay to analyze the effect of RALYL knockdown on the mRNA stability of BCL11B. Paired t-test was applied for comparisons between two groups, and two-way ANOVA was applied for comparisons among multiple groups. The experiment was repeated three times independently

RALYL knockdown inhibits the immune escape of SCLC cells

Finally, we overexpressed BCL11B and BUB3 in a RALYL-suppressed background, and BUB3 expression was restored upon BCL11B and BUB3 overexpression (Fig. 8A). We analyzed the immune escape of SCLC cells following RALYL knockdown and combined overexpression of BCL11B and BUB3. WB results showed that RALYL knockdown decreased PD-L1 expression in SCLC cells. BCL11B and BUB3 overexpression led to a significant increase in PD-L1 expression (Fig. 8B). RALYL knockdown increased cytotoxicity in the co-culture system (Fig. 8C), reduced SCLC cell survival (Fig. 8D), and enhanced SCLC cell apoptosis (Fig. 8E). Upregulation of BCL11B and BUB3 attenuated this effect, promoting SCLC cell survival and reducing apoptosis in the co-culture. Analysis of T-cell antitumor activation revealed that RALYL knockdown in SCLC cells increased the percentage of GZMB+ and Perforin+ cells, whereas additional upregulation of BCL11B and BUB3 produced the opposite effect (Fig. 8F, G).

Fig. 8.

Fig. 8

RALYL knockdown inhibits the immune escape of SCLC cells. A, WB detection of BCL11B and BUB3 protein expression in SCLC cells infected with RALYLKD + BCL11B or BUB3; B, WB detection of PD-L1 expression in SCLC cells infected with RALYLKD + BCL11B or BUB3; C, Cytotoxicity detection kit to detect cytotoxicity in the co-culture system; D, Luciferase activity assay to detect SCLC cell survival; E, TUNEL to detect cell apoptosis in the co-culture system; F-G, Flow cytometry to detect the percentage of positive cells for GZMB and Perforin in T cells after co-culture. Two-way ANOVA was applied for comparisons among multiple groups. The experiment was repeated three times independently

Knockdown of RALYL enhances the tumor-inhibiting effect of anti-PD-L1 immunotherapy

Finally, we established subcutaneous xenografts in humanized mice using NCI-H446 cells with RALYLKD and treated them with anti-PD-L1. RALYLKD reduced tumor growth (Fig. 9A) and tumor weight (Fig. 9B), accompanied by decreased expression of RALYL, BCL11B, and BUB3 in tumor tissues (Fig. 9C). TUNEL showed that RALYL knockdown increased apoptosis in tumor tissues (Fig. 9D). Analysis of CD8+ T cell infiltration in the tumor microenvironment revealed that RALYL knockdown promoted CD8+ T cell infiltration (Fig. 9E), while simultaneously increasing the levels of GZMB and Perforin in tumor tissues (Fig. 9F).

Fig. 9.

Fig. 9

Knockdown of RALYL enhances the tumor-inhibiting effect of the anti-PD-L1 antibody. A, Analysis of tumor volume in mice formed by SCLC cells with RALYL knockdown and treated with anti-PD-L1 antibody; B, Analysis of tumor weight in mice formed by SCLC cells with RALYL knockdown and treated with anti-PD-L1 antibody; C, WB detection of RALYL, BCL11B, and BUB3 expression in tumor tissues of mice in each group; D, TUNEL detection of apoptosis in tumor tissues; E, Flow cytometry of the population of CD3+CD8+ T cells in single-cell suspensions in tumor tissues; F, ELISA to detect GZMB and Perforin levels in tumor tissues. Two-way or one-way ANOVA was applied for comparisons among multiple groups, with five mice per group

Discussion

This study explored the role of BCL11B in immune escape in SCLC through cell and animal experiments and its upstream and downstream mechanisms. Overall, our findings uncovered that RALYL increased BCL11B mRNA stability and activated BUB3 transcription to induce immune escape of SCLC cells by enhancing PD-L1 expression (Fig. 10).

Fig. 10.

Fig. 10

RNA-binding protein RALYL enhances BCL11B stability to induce BUB3 activation and the PD-L1 pathway, thereby promoting immune escape in SCLC

BCL11B is crucial for several steps of T-cell precursor differentiation and the response of peripheral CD8+ T-cells in tumors [28]. Our findings elicited increased BCL11B expression in tumor tissues of SCLC patients, and patients with high BCL11B expression had worse prognoses, lower CD8+ T cell infiltration, and higher TNM stages. BCL11B was intricately linked to particular immune cells, and a predictive model involving BCL11B showed better predictive abilities than conventional clinical factors and was connected with increased infiltration of T cells in gastric cancer [29]. As revealed by Abe et al., the progression-free survival and overall survival were notably longer in patients with BCL11B-negative hepatocellular carcinoma than in BCL11B-positive cases [30]. GZMB is an ideal biomarker for immune response [31], and lung cancer patients with lower GZMB levels had poorer prognoses [32]. Interestingly, GZMB levels were increased in mucosal-associated invariant T cells from infected mice after BCL11B knockout [33]. The blockade of the PD-1/PD-L1 signaling pathway enhanced the antitumor immune response and improved therapeutic efficacy, and the administration of anti-PD-1/PD-L1 antibodies has demonstrated antitumor effects in clinical practice [34]. Our data demonstrate that tumor‑cell‑intrinsic BCL11B promotes immune escape in SCLC, as BCL11B knockdown in cancer cells enhanced CD8⁺ T‑cell cytotoxicity and improved the response to anti‑PD‑L1 therapy. The observed effect is mechanistically distinct from the well-established role of BCL11B in T-cell development and cytotoxic programming. In this context, BCL11B supports the generation of highly cytotoxic innate-like T cells, and its deletion alters T-cell immunophenotypes and reduces tumor spheroid growth by approximately 65% [35].

For the downstream target of BCL11B, our analyses uncovered that BCL11B was positively correlated with BUB3 expression, and SCLC patients with high expression of BUB3 had short survival. BUB3 mRNA expression was considerably correlated with CD8+ T cells, immune cell infiltration, lymph node metastasis, and shorter overall survival of patients with lung adenocarcinoma [36]. Mikolajewicz et al. also showed that perturbation of cycling-associated gene BUB3 led to reciprocal phenotypic shifts, which may be involved in intrinsic immune escape mechanisms in high-grade gliomas and glioblastomas [37]. Our rescue experiments confirmed that the repressive effect of BCL11B knockdown on SCLC cell immune escape was reversed by BUB3 overexpression. BUB3 has been identified to promote the deubiquitination of NCAPG by binding to it, which targets the SRC/STAT3 pathway and elevates PD-L1 expression in gastric cancer [38]. Our additional findings suggest that the promoting effects of BUB3 overexpression on PD-L1 expression were reversed by the STAT3 inhibitor Stattic, which was in line with a previous study that Stattic could weaken the immunofluorescence of PD-L1 by blocking and downregulating PD-L1 in metastatic breast cancer [39].

For the upstream mechanism of BCL11B, we noted that RALYL was positively correlated with BCL11B and BUB3 expression, and RALYL knockdown decreased PD-L1 expression in SCLC cells, increased cytotoxicity in the co-culture system, and decreased the percentage of GZMB+ and Perforin+ cells. RALYL expression was correlated with poor prognosis, poor differentiation, and metastasis in hepatocellular carcinoma patients, and RALYL silencing substantially suppressed cell proliferation and colony formation and reduced tumor volume [40]. RALYL is a potential mRNA vaccine antigen of SCLC and is expressed in SCLC subtypes with low immunity [15]. Little is reported about the involvement of RALYL in SCLC cell growth and immune escape, which highlights the novelty of our research.

Limitations of the study

The present study was not without its limitations: (i) RNA-binding proteins such as RALYL typically regulate multiple transcripts, and BCL11B itself likely controls a broader network of genes beyond BUB3. Subsequent studies employing RNA-seq, cross-linking immunoprecipitation sequencing (CLIP-seq), or RIP-seq will be necessary to establish pathway specificity and to delineate the broader regulatory landscape. (ii) Although our data suggest that the targeting of RALYL or this axis may have therapeutic implications, careful evaluation in clinically relevant models and patient cohorts will be required before considering therapeutic applications. (iii) The present study primarily focused on CD8+ T-cell infiltration and cytotoxicity. However, other key immune cell populations were not fully quantified in tumor tissues. Future studies employing flow cytometry or multiplex immunofluorescence will be necessary to delineate how this pathway influences diverse immune cell subsets and to provide a more holistic view of its role in shaping the tumor immune microenvironment. (iv) While the use of huPBMC-NOG mice provided a valuable platform, this model has inherent limitations. The reconstitution of the human immune system in NOG mice is incomplete, and variability in T-cell function can occur due to differences in donor PBMCs and engraftment efficiency [41]. The employment of more advanced humanized mouse models or patient-derived xenografts with improved immune reconstitution in future studies will be essential for the validation of the conclusions.

In summary, our study identifies a tumor-cell-intrinsic role for BCL11B in promoting immune escape in SCLC through a proposed RALYL/BCL11B/BUB3/PD-L1 regulatory axis. By distinguishing this particular function of the cancer cells from the well-established role of BCL11B in T-cell development and cytotoxic programming, our findings highlight a previously unrecognized mechanism by which SCLC cells evade CD8+ T-cell-mediated killing. These results suggest that BCL11B inhibition represents a promising therapeutic strategy to improve immunotherapy efficacy and potentially patient survival in SCLC.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary Material 1 (2.9MB, docx)
Supplementary Material 3 (21.8KB, docx)

Acknowledgements

We thank the Key Research and Development Program of Heilongjiang (No. 2022ZX06C11), the Nn10 Program of Harbin Medical University Cancer Hospital (No. Nn10pv2017-04), the National Natural Science Foundation of China (No. 81672931), the Climbing Program of Harbin Medical University Cancer Hospital (No. PDYS2024-01), and the Haiyan Fund of Harbin Medical University Cancer Hospital (No. JJZD2021-04)for funding support.

Author contributions

Jiayue Shao: Conceptualization, Methodology, Writing – original draft, Formal analysis, Project administration. Shuangqing Liu: Methodology, Visualization, Formal analysis. Ling Qin: Software, Data curation, Supervision. Ningning Fan and Qi Sun: Investigation, Methodology, Software. Qingwei Meng: Funding acquisition, Project administration, Resources, Writing – review and editing.

Funding

This work was supported by the Key Research and Development Program of Heilongjiang (No. 2022ZX06C11) and the Nn10 Program of Harbin Medical University Cancer Hospital (No. Nn10pv2017-04), the National Natural Science Foundation of China (No. 81672931), the Climbing Program of Harbin Medical University Cancer Hospital (No. PDYS2024-01), and the Haiyan Fund of Harbin Medical University Cancer Hospital (No. JJZD2021-04).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethical approval

All patients signed an informed consent form. The clinical study was approved and reviewed by the ethical approval committee of Harbin Medical University Cancer Hospital and adhered to the tenets of the Declaration of Helsinki. The animal study was approved by the Ethics Review Committee of Harbin Medical University Cancer Hospital (approval no. KY2021-15) and complied with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.

Informed consent

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.C.M. Rudin, E. Brambilla, C. Faivre-Finn et al., Small-cell lung cancer. Nat. Rev. Dis. Primers. 7(1), 3 (2021). 10.1038/s41572-020-00235-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Z. Megyesfalvi, C.M. Gay, H. Popper et al., Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 73(6), 620–652 (2023). 10.3322/caac.21785 [DOI] [PubMed] [Google Scholar]
  • 3.Y. Wang, S. Zou, Z. Zhao et al., New insights into small-cell lung cancer development and therapy. Cell. Biol. Int. 44(8), 1564–1576 (2020). 10.1002/cbin.11359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.W.J. Petty, L. Paz-Ares, Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncol. 9(3), 419–429 (2023). 10.1001/jamaoncol.2022.5631 [DOI] [PubMed] [Google Scholar]
  • 5.R. Rui, L. Zhou, S. He, Cancer immunotherapies: advances and bottlenecks. Front. Immunol. 14, 1212476 (2023). 10.3389/fimmu.2023.1212476 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.M.T. Daher, P. Bausero, O. Agbulut et al., Bcl11b/Ctip2 in Skin, Tooth, and Craniofacial System. Front. Cell. Dev. Biol. 8, 581674 (2020). 10.3389/fcell.2020.581674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.M.J. Lennon, S.P. Jones, M.D. Lovelace et al., Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease. Front. Cell. Neurosci. 11, 89 (2017). 10.3389/fncel.2017.00089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.M. Maluski, A. Ghosh, J. Herbst et al., Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. J. Clin. Invest. 129(12), 5108–5122 (2019). 10.1172/JCI126350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.T. Sidwell, E.V. Rothenberg, Epigenetic Dynamics in the Function of T-Lineage Regulatory Factor Bcl11b. Front. Immunol. 12, 669498 (2021). 10.3389/fimmu.2021.669498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.P.M.A. Silva, H. Bousbaa, BUB3, beyond the simple role of partner. Pharmaceutics. 14(5), (2022). 10.3390/pharmaceutics14051084 [DOI] [PMC free article] [PubMed]
  • 11.C. Wang, D. Cheng, C. Pan et al., Research progress of Bub3 gene in malignant tumors. Cell. Biol. Int. 46(5), 673–682 (2022). 10.1002/cbin.11740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Q. Ye, N.L. Guo, Hub genes in non-small cell lung cancer regulatory networks. Biomolecules. 12(12), (2022). 10.3390/biom12121782 [DOI] [PMC free article] [PubMed]
  • 13.J. Ma, L. Sun, W. Gao et al., RNA binding protein: coordinated expression between the nuclear and mitochondrial genomes in tumors. J. Transl Med. 21(1), 512 (2023). 10.1186/s12967-023-04373-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.H. Qin, H. Ni, Y. Liu et al., RNA-binding proteins in tumor progression. J. Hematol. Oncol. 13(1), 90 (2020). 10.1186/s13045-020-00927-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Y. Wei, L. Zheng, X. Yang et al., Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer. Oncologist. 28(11), e1052–e64 (2023). 10.1093/oncolo/oyad193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.H. Guo, Y. Xiao, Z. Yuan et al., Inhibition of STAT3(Y705) phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells. Cell. Death Discov. 8(1), 116 (2022). 10.1038/s41420-022-00922-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.J.B. Hiatt, H. Sandborg, S.M. Garrison et al., Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clin. Cancer Res. 28(20), 4551–4564 (2022). 10.1158/1078-0432.CCR-22-1128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.T. Daunke, S. Beckinger, S. Rahn et al., Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Front. Immunol. 14, 1157397 (2023). 10.3389/fimmu.2023.1157397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Q. Dong, T. Yu, B. Chen et al., Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway. JCI Insight. 8(21), (2023). 10.1172/jci.insight.165268 [DOI] [PMC free article] [PubMed]
  • 20.M. Liang, Z. Sun, X. Chen et al., E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells. J. Exp. Clin. Cancer Res. 42(1), 275 (2023). 10.1186/s13046-023-02862-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.L. Zhang, H. Yu, A. Badzio et al., Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J. Thorac. Oncol. 10(7), 1083–1090 (2015). 10.1097/JTO.0000000000000562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.B. Wang, Y. Yin, A. Wang et al., SMR-guided molecular subtyping and machine learning model reveals novel prognostic biomarkers and therapeutic targets in non-small cell lung adenocarcinoma. Sci Rep. 15(1), 1640 (2025). 10.1038/s41598-025-85471-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.L. Drivsholm, L.I. Paloheimo, K. Osterlind, A. Chromogranin, a significant prognostic factor in small cell lung cancer. Br. J. Cancer. 81(4), 667–671 (1999). 10.1038/sj.bjc.6690745 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Y.C. Chang, M.H. Chan, C.H. Li et al., Metabolic protein phosphoglycerate kinase 1 confers lung cancer migration by directly binding HIV Tat specific factor 1. Cell. Death Discov. 7(1), 135 (2021). 10.1038/s41420-021-00520-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.L. He, Y. Li, X. Huang et al., The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer. Onco Targets Ther. 12, 5897–5906 (2019). 10.2147/OTT.S210223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Y. Xu, Z. Liang, C. Li et al., LCMR1 interacts with DEK to suppress apoptosis in lung cancer cells. Mol. Med. Rep. 16(4), 4159–4164 (2017). 10.3892/mmr.2017.7095 [DOI] [PubMed] [Google Scholar]
  • 27.D. Douchi, H. Ohtsuka, K. Ariake et al., Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/beta-catenin signaling pathway. Cancer Lett. 365(1), 132–140 (2015). 10.1016/j.canlet.2015.05.023 [DOI] [PubMed] [Google Scholar]
  • 28.J.M. Garcia-Aznar, S. Alonso Alvarez, T. Bernal Del Castillo, Pivotal role of BCL11B in the immune, hematopoietic and nervous systems: a review of the BCL11B-associated phenotypes from the genetic perspective. Genes Immun. 25(3), 232–241 (2024). 10.1038/s41435-024-00263-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.X. Sui, G. Wu, Immune landscape and prognostic gene signatures in gastric cancer: implications for cachexia and clinical outcomes. Front. Immunol. 14, 1297363 (2023). 10.3389/fimmu.2023.1297363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.H. Abe, K. Kamimura, S. Okuda et al., BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. Cancer Med. 12(14), 15650–15663 (2023). 10.1002/cam4.6167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.X. Li, G. Chen, K. Wu et al., Imaging and monitoring of granzyme B in the immune response. Wiley Interdiscip Rev. Nanomed. Nanobiotechnol. 16(1), e1928 (2024). 10.1002/wnan.1928 [DOI] [PubMed] [Google Scholar]
  • 32.Y. Hayashi, A. Ueyama, S. Funaki et al., In situ analysis of CCR8(+) regulatory T cells in lung cancer: suppression of GzmB(+) CD8(+) T cells and prognostic marker implications. BMC Cancer. 24(1), 627 (2024). 10.1186/s12885-024-12363-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.T.T. Drashansky, E.Y. Helm, N. Curkovic et al., BCL11B is positioned upstream of PLZF and RORgammat to control thymic development of mucosal-associated invariant T cells and MAIT17 program. iScience. 24(4), 102307 (2021). 10.1016/j.isci.2021.102307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Y. Kui, F. Tong, R. Zhang et al., Strategies to target PD-1/PD-L1 in the tumor microenvironment. Cell. Oncol. (Dordr). 49(2), (2026). 10.1007/s13402-026-01181-x [DOI] [PMC free article] [PubMed]
  • 35.H. Forkel, P. Grabarczyk, M. Depke et al., BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood alphabeta CD8 + T cells. Oncoimmunology. 11(1), 2148850 (2022). 10.1080/2162402X.2022.2148850 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.X. Li, T. Wang, M. Li et al., Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis. Aging (Albany NY). 15(3), 810–829 (2023). 10.18632/aging.204517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.N. Mikolajewicz, N. Tatari, J. Wei et al., Functional profiling of murine glioma models highlights targetable immune evasion phenotypes. Acta Neuropathol. 148(1), 74 (2024). 10.1007/s00401-024-02831-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.S. Zhou, L. Xiao, L. Hu et al., CAFs promote immune evasion in gastric cancer through histone lactylation-mediated suppression of NCAPG ubiquitination. J. Transl Med. 23(1), 989 (2025). 10.1186/s12967-025-07013-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Z. Qiu, Z. Lu, J. Huang et al., Self-reinforced photodynamic immunostimulator to downregulate and block PD-L1 for metastatic breast cancer treatment. Biomaterials. 303, 122392 (2023). 10.1016/j.biomaterials.2023.122392 [DOI] [PubMed] [Google Scholar]
  • 40.X. Wang, J. Wang, Y.M. Tsui et al., RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-beta2. Nat. Commun. 12(1), 1518 (2021). 10.1038/s41467-021-21828-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Y.M. 2 Morillon nd, A. Sabzevari, J. Schlom et al., The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Anticancer Res. 40(10), 5329–5341 (2020). 10.21873/anticanres.14540 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (2.9MB, docx)
Supplementary Material 3 (21.8KB, docx)

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Cellular Oncology are provided here courtesy of Springer

RESOURCES